Advertisement

Topics

Galapagos Company Profile

02:04 EST 15th December 2018 | BioPortfolio

We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected diseases areas for which there is a need for effective and safe medicines.
We focus on developing drugs that stop or reverse a disease state using novel targets that we identify through a patent protected genomics platform. To maximise the potential of the proprietary technology, we provide access to our target and drug discovery platform through our services division BioFocus DPI.Galapagos focuses its internal programs on developing new drugs in the bone and joint diseases- osteoarthritis, osteoporosis and rheumatoid arthritis. BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery to validation and drug discovery services through to delivery of pre-clinical candidates. In addition, BioFocus DPI provides adenoviral reagents for rapid identification and validation of novel drug targets, natural and synthetic compound libraries for screening, and compound management facilities for compound delivery to multiple screening centers.

Location

BioFocus DPI9640 Towne Centre Drive
San Diego
California
92121
United States of America

Contact

Phone: 1 858 455 8600
Fax: 1 858 546 3081
Email: bd@glpg.com


News Articles [161 Associated News Articles listed on BioPortfolio]

Galapagos: 3 Pillars to Success, The Galapagos Model

In this episode of PharmaTelevision News Review,filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to Onno Van De Stolpe, CEO of Galapagos

Galapagos: Technology Platforms and Future Plans

In this episode of PharmaTelevision News Review, Fintan Walton talks with Onno Van de Stolpe, CEO at Galapagos. Filmed at BioBusiness 2010 in London, England, they discuss: • How Galapagos has handl...

Galapagos NV: Galapagos announces launch of proposed public offering

Mechelen, Belgium, 12 September 2018, 22.45 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other condi...

Galapagos NV: Galapagos and AbbVie restructure CF collaboration

Mechelen, Belgium, Chicago, US; 24 October 2018; 22.02 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) and AbbVie, Inc (NYSE: ABBV) announce a restructuring of their cystic fib...

Galapagos NV: Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announc...

Galapagos NV: MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Mechelen, Belgium and Planegg/Munich, Germany; 12 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announc...

Galapagos: Onno van de Stolpe, CEO

Onno van de Stolpe talks to Fintan Walton, about Galapagos' current business model and overall strategic outlook. They discuss the integration of BioFocus following its acquisition by Galapagos in Nov...

Galapagos NV: Galapagos raises $300 million gross proceeds in a U.S. public offering

Mechelen, Belgium, 13 September 2018, 03.00 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $300 million gross ...

Drugs and Medications [0 Results]

None

PubMed Articles [13 Associated PubMed Articles listed on BioPortfolio]

Galapagos Islands Endemic Vertebrates: A Population Genetics Perspective.

The organisms of the Galapagos Islands played a central role in the development of the theory of evolution by Charles Darwin. Examination of the population genetics factors of many of these organisms ...

Intestinal parasites in Galapagos sea lions (Zalophus wollebaeki) Sivertsen, 1953 on San Cristóbal Island, Galápagos, Ecuador.

Knowledge regarding endoparasites of Galapagos sea lions, Zalophus wollebaeki Sivertsen, 1953, is limited to 1 report. Herein, we examined feces extracted from the lower gastro-intestinal tract of 15 ...

EVALUATION OF THE OPHTHALMIC DISEASE AND HISTOPATHOLOGIC EFFECTS DUE TO THE OCULAR TREMATODE PHILOPHTHALMUS ZALOPHI ON JUVENILE GALAPAGOS SEA LIONS ( ZALOPHUS WOLLEBAEKI).

The Galapagos sea lion ( Zalophus wollebaeki) is an otariid species endemic to the Galapagos archipelago and is currently listed as endangered. The ocular trematode Philophthalmus zalophi was recently...

Genome-wide assessment of diversity and divergence among extant Galapagos giant tortoise species.

Genome-wide assessments allow for fuller characterization of genetic diversity, finer-scale population delineation, and better detection of demographically significant units to guide conservation comp...

Burden of exposure to infectious bursal disease virus, infectious bronchitis virus, Newcastle disease virus, Mycoplasma gallisepticum, and intestinal parasites in introduced broiler chickens on the Galapagos.

Diseases in introduced broilers can possibly spill over to wild birds on the Galapagos. Knowledge about the current burden of exposure to pathogens in broilers on the Galapagos is very limited. The ob...

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Galapagos nv

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs...

Discovery Partners International

Discovery Partners recently completed the sale of all of the stock of Discovery Partners’ operating subsidiaries and all of Discovery Partners’ material operating assets pursuant to a stock and as...

Galapagos

We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected disea...

More Information about "Galapagos" on BioPortfolio

We have published hundreds of Galapagos news stories on BioPortfolio along with dozens of Galapagos Clinical Trials and PubMed Articles about Galapagos for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galapagos Companies in our database. You can also find out about relevant Galapagos Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record